2026 ETA Guideline: Interference in Immunoassay Measurements Used in Assessment of Thyroid Function

Full title: 2026 ETA guideline on interference in immunoassay measurements used in assessment of thyroid function Issuer: European Thyroid Association（ETA）, published in European Thyroid Journal, August 2026 Core positioning: Multidisciplinary guideline for clinicians and laboratory specialists. Key principle: When TFT results conflict with clinical picture, assay interference must be excluded before diagnosing rare disorders (thyroid hormone resistance, TSH-secreting pituitary adenoma). Emphasizes close clinician-laboratory communication, pre-analytical screening and tiered interference verification strategy, compatible with prior ETA/BTA thyroid storm consensus and KTA DTC follow-up guidelineNational C....

1. Background & Clinical Consequence

Immunoassays for TSH, FT4, FT3, Tg, TRAb are widely used but susceptible to interference. Interference may cause false elevation or suppression, leading to misdiagnosis, unnecessary medication, repeated imaging and inappropriate surgery. Interference categories:

1. Drug/exogenous interference (biotin is the most prevalent)
2. Endogenous antibody interference (heterophile antibodies, HAMA, macro-TSH, anti-thyroid hormone autoantibodies, anti-streptavidin/anti-ruthenium antibodies)
3. Binding protein abnormalities (TBG variants, dysalbuminemic hyperthyroxinemia)
4. Pre-analytical artifacts

2. Major Types of Interference & Mechanism

2.1 Biotin interference (streptavidin-biotin assay platforms)

• Sandwich assays (TSH, Tg): excess biotin → falsely low TSH
• Competitive assays (FT4, FT3, TRAb): excess biotin → falsely high FT4 / FT3

The pattern mimics Graves’ hyperthyroidism.

• Recommendation: Stop biotin supplements for 48–72 hours before blood sampling. Interference usually occurs with doses ≥5 mg daily, most common at 10 mg/day or higher. Low-dose biotin (<1 mg) rarely causes meaningful bias.

2.2 Heterophilic antibodies / Human anti-mouse antibodies (HAMA)

Heterophile antibodies cross-react with assay capture/detection antibodies, may falsely raise or lower TSH. Common in autoimmune disease, patients exposed to animal antibodies or biologics. Rheumatoid factor is a frequent confounder.

• Screening: serial dilution, heterophile blocking reagent pre-treatment, alternative assay platform.

2.3 Macro-TSH

Complex of TSH bound to endogenous immunoglobulin, resulting in falsely elevated TSH, mimicking subclinical hypothyroidism. Patients are clinically euthyroid.

• Confirmation: PEG precipitation; TSH falls after removing macrocomplex.

2.4 Thyroid hormone autoantibodies (anti-T4 / anti-T3 autoantibodies)

Bind endogenous thyroid hormone, disturb free hormone immunoassays; FT4/FT3 results can be falsely high or low, assay-dependent.

2.5 Anti-streptavidin / anti-ruthenium antibodies

Rare, platform-specific interference for electrochemiluminescence assays; persistent abnormal TFT despite biotin withdrawal.

2.6 Binding protein variants

1. Dysalbuminemic hyperthyroxinemia (DAH): mutant albumin binds T4 tightly; total T4 elevated, FT4 immunoassay may be falsely high, patient euthyroid.
2. TBG deficiency / excess: alters total T4/T3; free hormone assays are preferred, but some FT4 kits are also vulnerable.

3. Clinical Red Flags (trigger interference workup)

Start interference investigation when laboratory result inconsistent with clinical status:

1. Discordant TFT pattern: suppressed TSH with non-elevated FT4/FT3, or elevated TSH with normal/high FT4, unexplained by medication/pituitary disease.
2. No clinical symptoms of hyperthyroidism/hypothyroidism despite markedly abnormal lab values.
3. TFT fails to respond appropriately to L-T4 or antithyroid drug dose adjustment.
4. Discrepant results between different immunoassay platforms.
5. Unusual TRAb/Tg results inconsistent with thyroid ultrasound and clinical context.
6. Suspected central hyperthyroidism, thyroid hormone resistance before pituitary imaging or genetic testing.

4. Stepwise Diagnostic Algorithm

1. Pre-analytical review: Medication history (biotin, amiodarone, heparin), supplement intake, sample quality (fibrin, haemolysis, lipemia). Repeat sampling after biotin washout if applicable.
2. Repeat on an alternative immunoassay platform.
3. Serial dilution test: Check linearity; non-parallel dilution suggests antibody interference.
4. Block heterophile interference: Heterophile blocking tubes.
5. PEG precipitation: Identify macro-TSH and Ig-bound hormone complexes.
6. Reference method: LC-MS/MS for FT4/FT3 (gold standard to confirm true free hormone concentration).
7. Specialized testing: TBG/albumin genotyping, thyroid hormone resistance genetic testing only after interference fully ruled out.

5. Assay-Specific Recommendations

1. TSH: Macro-TSH and heterophile antibodies are the most common culprits.
2. FT4 / FT3: Biotin, anti-hormone autoantibodies, DAH; LC-MS/MS is the preferred confirmatory method.
3. TRAb: Biotin interference can produce false positive or false negative results; critical before diagnosing Graves’ disease.
4. Thyroglobulin (Tg): Biotin and heterophile interference; anti-Tg antibody must be measured alongside Tg, consistent with KTA DTC surveillance guideline.

6. Special Patient Populations

1. Autoimmune rheumatic disease (RA, Sjogren): higher risk of heterophile/RF interference.
2. Patients on biotin for hair/nail supplements or multiple sclerosis therapy: mandatory medication review.
3. Patients previously treated with murine antibodies or rituximab: elevated risk of HAMA.
4. Patients evaluated for TSHoma / thyroid hormone resistance: interference exclusion is prerequisite before pituitary MRI and genetic testing.

7. Reporting & Laboratory-Clinical Collaboration

• Laboratories should comment on assay platform vulnerability and flag suspicious discordant results.
• Clinicians must provide clinical context to lab, rather than only ordering repeat TFT blindly.
• Avoid empiric treatment solely based on isolated abnormal immunoassay results without clinical correlation.

8. Evidence Gaps

1. The prevalence of many rare interferences varies substantially by assay platform and population.
2. Standardized protocols for anti-streptavidin/anti-ruthenium antibody detection are lacking.
3. Cost and accessibility of LC-MS/MS limit routine use in primary care.

9. Cross alignment with prior guideline series

1. This 2026 ETA guideline: laboratory immunoassay interference, resolving discordant thyroid biochemistry, critical prerequisite for reliable TFT interpretation.
2. ETA/BTA 2026 thyroid storm consensus: thyroid storm relies on TFT + clinical judgement; interference can mimic or obscure thyrotoxicosis.
3. KTA 2026 DTC follow-up guideline: Tg and anti-Tg monitoring for thyroid cancer recurrence, biotin and heterophile interference may cause false Tg results.
4. NASIT 2026 thyroid embolization statement / 2026 Italian post-op hypoparathyroidism guideline: thyroid and parathyroid disease workup require trustworthy TFT and calcium/PTH assays.

Disclaimer: This summary is for academic learning only, not for laboratory operation or direct clinical decision-making. Interference investigation requires joint review by endocrinologists and clinical biochemistry specialists